Status:
COMPLETED
Exploratory Study to Assess the Pharmacokinetics of AZD5985
Lead Sponsor:
AstraZeneca
Conditions:
Healthy
Eligibility:
MALE
18-45 years
Phase:
PHASE1
Brief Summary
The aim of this exploratory study is to assess the pharmacokinetics of increasing oral doses of AZD5985 in healthy male volunteers
Eligibility Criteria
Inclusion
- Provision of signed, written and dated informed consent prior to any study specific procedures.
- Healthy male subjects aged 18 to 45 years (inclusive).
- Have a body mass index (BMI) between 19 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg.
- Be non-smoker or ex-smoker who has stopped smoking (or using other nicotine products) for \>6 months prior to study start.
Exclusion
- History or presence of any clinically significant disease or disorder in the opinion of the investigator.
- Any clinically relevant abnormal findings in physical examination, clinical chemistry, haematology, urinalysis, vital signs or ECG at baseline in the opinion of the investigator.
- Participation in another investigational drug study within 3 months before Visit 2 or participation in a method development study (no drug) 1 month prior to Visit 2
Key Trial Info
Start Date :
November 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2009
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT00799331
Start Date
November 1 2008
End Date
February 1 2009
Last Update
June 9 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Berlin, Germany